Musclepharm Corp

Musclepharm — Investor Presentation (August 2015)

24 slides from Musclepharm's investor presentation, Aug 11, 2015

  1. Slide 1: MusclePharm

    LL md MUSCLEPHARM, [DRA SEience. |

  2. Slide 2: Forward Looking Statement

    FOR W ARD LOOKING S T A TEMEN T : I n f orm a tion included he r ein co n t ains f o r w a r d looking s t a t eme n t s. F o r w a r d - looking s t a t eme n t s a r e ide n tified b y wo r ds such as ‘ ‘ e xpect , ’ ‘ ‘ plan , ’’ ‘ ‘ will , ’’ ‘ ‘ should , ’’ ‘ ‘ could , ’’ “ a n ticip a t e , ”

  3. Slide 3: MusclePharm: Fueling the Engine of Sport Business

    PG. 3 MUSCLEPHARM: FUELING THE ENGINE OF SPO R T™ BUSINESS Our goal is t o se r v e the needs o f all a thle t es, while f ueling the engine o f spor t s f or all ages and gende r s. MusclePhar m ’ s p r oduct lines a r e designed primarily f or specific a thletic use and a thle t es' needs, d a y i

  4. Slide 4: Built From the Ground Up

    PG. 4 2 01 0 $150,000,00 0 $125,000,00 0 $ 11 0,87 7 ,591 $ 1 00,000,00 0 $75,000,000 $6 7 ,055,215 $50,000,000 $25,000,000 $ 1 7 ,212,636 $3,202,687 $ 1 75,000,00 0 $200,000,00 0 $220,000,00 0 2 01 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 15 E $ 1 7 7 ,289,00 0 $2 1 0,000,00 0 $220,000,00 0 BUI L T FROM THE G

  5. Slide 5: Well-Established Base Growing Distribution Network

    PG. 5 WEL L - E S T ABLISHED BA SE GROWING DI S TRIBUTION NETWORK • Our nutritional suppleme n t s a r e av ailable f or pu r chase in mo r e than 35 , 000 U .S. r e t ail outle t s, 100 online r e t ail outle t s, and mo r e than 1 10 i n t ern a tional cou n tries • P r o vides pl a t f orm t o la

  6. Slide 6: Capturing a Large and Growing Market

    PG. 6 A cco r ding t o the “Nutrition Busine s s Journal , ” The spor t s nutrition & weig h t lo s s mar k et in the Uni t ed S t a t es w as estim a t ed t o be app ro xim a t ely $37 billion in 2 0 1 4 . In r ece n t y ea r s, nutritional suppleme n t companies, anal y s t s, public a tions and o

  7. Slide 7: Our Products: Increasing Market Share Legacy Build

    PG. 7 • E f f ecti v e Science - Based P r oduc t s • Our p r oduc t s a r e the r esult o f a si x - s t age p r oce s s i nv olving r ecogni z ed nutrition scie n tis t s, doc t o r s and p r o f e s sional a thle t es a t our MP Spor t s Science Insti t u t e • E v e r y p r oduct is a f ormul a

  8. Slide 8: MusclePharm Brand

    PG. 8 T A G LINE R eal Science. R eal A thle t e s ™ T ARGET A UDIENCE • Prima r y Mar k et: Male 18 - 35 age g r oup • Seconda r y Mar k et: Male 3 5 + age g r oup L A UNCHED 2008 NUMBER OF PRODUC T S 15 PRODUC T S INC L UDE • Amin o 1 ™ • Armo r - V ® • A s sault • B a t tle F uel X T ™ • • • • Co

  9. Slide 9: FitMiss Brand

    PG. 9 T A G LINE S TRONG IS THE NEW SE X Y® T ARGET A UDIENCE • Prima r y Mar k et: F emale 25 - 45 age g r oup • Seconda r y Mar k et: F emale <25 age g r oup L A UNCHED 2 0 13 NUMBER OF PRODUC T S 8 PRODUC T S INC L UDE • FitMi s s Bur n ™ • FitMi s s Balanc e ™ • FitMi s s Cleans e ™ • FitMi s s

  10. Slide 10: Arnold Schwarzenegger Series

    PG. 10 T A G LINE Build Y our L egac y ™ T ARGET A UDIENCE: • Prima r y Mar k et: Male 18 - 45 age g r oup • Seconda r y Mar k et: Male 4 5 + age g r oup L A UNCHED 2 0 13 NUMBER OF PRODUC T S 7 PRODUC T S INC L UDE • I r on CR E3 ™ • I r on Cu t s ™ • I r on D r ea m ™ • I r on P ac k ™ • I r on Pu

  11. Slide 11: Core Strengths

    PG. 11 CORE S TREN G THS 1. PRODUCING T OP QUALITY PRODUCTS 2. BA CKED B Y REAL A THLETES – REAL SCIENCE 3. CU ST OMER EXPERIENCE - UNM A T CHED CONNECTION WITH CU ST OMERS

  12. Slide 12: Establishing Trust: Producing Top Quality Products

    PG. 12 E S T ABLISHING TRU S T : PRODUCING T OP QUALITY PRODUCTS • Insti t utional R e view Boa r d - app r ov ed clinical trials in - house a t the 3 0, 000 sq. ft. MusclePharm Spor t s Science Insti t u t e • Quali t y co n t r ol and scie n tific t eam comprised o f 20 scie n tis t s, pharmacis t

  13. Slide 13: Building the Brand: The Athletes Company

    PG. 13 BUILDING THE BRAND: THE A THLETES COM P ANY ORGANIZ A TIONS: • O f ficial Suppleme n t o f U F C, now in ov er 800M homes Globally • O f ficial Suppleme n t o f U S A Wr estling • B r and Amba s sado r s: Arnold Sch w a rz enegge r , Collin K aepernick, Jen Sel t e r , T iger W oods

  14. Slide 14: Earning Loyalty: Connecting with Customers

    PG. 14 EARNING L O Y A L T Y : CONNECTING WITH CU ST OMERS W e h av e built one o f the st r ongest social communities in the indust r y • Daily W or k ou t s, T r aining A dvice and Diet Plans b y our A thle t es and MP Doc t o r s • Social Media & Cus t omer Command Ce n t er in Columbus, Ohio • P

  15. Slide 15: Creating Awareness

    PG. 15 CRE A TIN G A W AREN ESS: • O f ficial suppleme n t sponsor o f the Ultim a t e Fig h ting Championship • Sponso r ed ov er 100 U F C fig h t e r s including Ande r son Sil v a, Jon “Bone s ” Jones, Qui n t on “ R ampag e ” Jac k son, Cl a y Guida, and R ashad E v ans

  16. Slide 16: Generating Buzz

    PG. 16 GENER A TING BU ZZ

  17. Slide 17: Growing the Company: Core Strategies

    PG. 17 EX P AND CURRENT PRODUCT LINE • MusclePharm b r and will be launching ov er 75 new p r oduct of f erings in 2 0 1 4 • The FitMi s s b r and will be launching ov er 20 new p r oduct of f erings in 2 0 1 4 • The Arnold b r and will be launching ov er 40 new p r oduct of f erings in 2 0 1 4 GROW

  18. Slide 18: Recent Developments

    PG. 18 • A dded T iger W oods and John n y Manziel as our newest b r and amba s sado r ’ s • S t r engthened r e t ail p r esence with GNC • Published double – blind placebo – co n t r olled clinical trial co n firming s a f e t y and ef ficiency o f M P ’ s p r e - wor k out A s saul t ™ RECENT DEV

  19. Slide 19: Enhancing Profitability, Building Value

    PG. 19 ENHANCING PROFI T ABILITY BUILDING V ALUE DRIVE REVENUE GRO W TH AND C A P TURE MARKET SHARE • Co n tinue building the b r and with new and ex citing p r oduc t s • High r e t e n tion with cus t ome r s th r ough one o f kind cus t omer e xperience • A dditional channels o f distribution • A

  20. Slide 20: Strong Growth Transitioning to Profitability

    PG. 20 S TRONG GROW TH TRANSITIONING T O PROFI T ABILITY 0 2 0 14 2 0 15 2 0 13 2 0 12 2 0 1 1 NET REVENUE S GROSS MARGINS EPS $ 1 7 ,212 , 636 $6 7 , 055, 215 $1 1 0 ,8 7 7 , 5 9 1 $ 1 7 7 ,28 9, 000 $210M - $220M 1 3 .8 % 21 . 4 % 2 9 .9 % 3 1 . 6 % 3 2 % - 33% - $ 70 . 3 - $ 1 3. 0 - $2. 5 - $ 1.

  21. Slide 21: Global Channel Sales

    PG. 21 20 1 4 GLO B A L CHANNEL S ALES $ 1 7 7 MILLION SP E CIA L T Y INTERN A TIO NAL FD M 45 % 40 % 15 %

  22. Slide 22: MusclePharm Team

    PG. 22 MUSCLEPH ARM TEAM BRAD P Y A T T CHIEF EX E CUTIVE OFFICER • F ounded MusclePharm® in 2008 a f t er pl a ying p r o f e s sional f o o tball f or s ev en y ea r s, the majori t y with the Indianapolis Col t s • Fi r sthand e xperience with t aking suppleme n t s t o enhance pe r f ormance • B

  23. Slide 23: Scientific Advisory Board

    PG. 23 SCIENTIFIC ADVISO R Y B O ARD DR. ERIC SERRAN O , M. D . M. D . – CHIEF F ORMUL A T OR & MEDI C AL A D VISOR • Conside r ed one o f the leading spor t s nutrition doc t o r s in the cou n t r y • Clie n t s include a wide ar r a y o f a thle t es f r om the NFL, NHL, and MLB; as well as eli t

  24. Slide 24: Why Invest

    PG. 24 PG. 24 • L eading the industry with science - based p r oduc t s t es t ed f or s a f e t y and e f ficacy • L a r ge and g r owing mar k et, with inc r easing ado p tion o f MusclePharm b r ands • P r oduc t s c r e a t ed b y a thle t es f or a thle t es and p r om o t ed b y a thle t es •

MusclePharm — Investor Presentation (August 2015) on 6ix